Instrumento Inactivo

Otros idiomas Alexion Pharmaceuticals, Inc.

Acciones

ALXN

US0153511094

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Alexion Pharmaceuticals, Inc.'s VOYDEYA Receives Approval in US Add-On Therapy to Ravulizumab or Eculizumab for Treatment of Extravascular Hemolysis in Adults with the Rare Disease PNH	01/04
Alexion Announces Long-Term Alpha Phase III Trial Data Shows Danicopan as Add-On to Standard of Care C5 Inhibitor Therapy ULTOMIRIS	11/12
Alexion Pharmaceuticals, Inc. completed the acquisition of Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc..	19/09/23
Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases	08/09/23
Alexion Pharmaceuticals, Inc. entered a definitive purchase agreement to acquire Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc. for $1 billion.	28/07/23
Astrazeneca continue à muscler son portefeuille de médicaments	05/06/23
AstraZeneca showcases scientific advances across rare and malignant haematological conditions at EHA 2023	17/05/23
Koselugo approved in China for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas	08/05/23
JCR Pharmaceuticals Co., Ltd. Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoR for Neurodegenerative Disease	30/03/23
AstraZeneca: embellie en 2022 mais déclin attendu des médicaments anti-Covid	09/02/23
AstraZeneca: embellie des résultats 2022	09/02/23
AstraZeneca showcases strength of hematology portfolio and pipeline across multiple hard-to-treat conditions at ASH 2022	01/12/22
Alexion AstraZeneca Rare Disease Completes Acquisition of LogicBio Therapeutics	17/11/22
Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. from a group of shareholders.	15/11/22
AstraZeneca expands global footprint in rare disease with availability of first Alexion rare disease therapy for patients in China	11/11/22
Alexion Pharmaceuticals, Inc. Aims to Advance Nmosd Treatment Landscape with Exceptional Ultomiris® (Ravulizumab-Cwvz) Efficacy Data At Ectrims 2022	12/10/22
Alexion, AstraZeneca Rare Disease to Acquire LogicBio Therapeutics to Accelerate Growth in Genomic Medicine	04/10/22
Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. from a group of shareholders for $68.2 million.	03/10/22
Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neurofibromatosis type 1	28/09/22
Koselugo approved in Japan for paediatric patients with plexiform neurofibromas in neurofibromatosis type1	28/09/22

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas Alexion Pharmaceuticals, Inc.

Acciones

ALXN

US0153511094

Otros idiomas

Filtros